Drug Profile

MBX SD 202

Alternative Names: MBX-SD-202

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MyBiotics
Class Antibacterials; Bacteria
Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Feb 2025 No recent reports of development identified for phase-I development in Clostridium-difficile-infections(In volunteers) in Israel (PO, Capsule)
28 Jan 2022 MyBiotics plans clinical trials of MBX SD 202 for Clostridium difficile infections (Recurrent) and closely related medical indications, during 2022 and 2023
24 Jan 2022 Phase-I clinical trials in Clostridium difficile infections (In volunteers) in Israel (PO), prior to January 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com